Quantcast

Europe’s Leading Genetics Experts Join FDNA’s Scientific Advisory Board

June 30, 2014

NEW YORK, June 30, 2014 /PRNewswire/ –

FDNA(R) (http://www.fdna.com) – a pioneer in computer-aided dysmorphology analysis is
proud to announce that four of Europe’s leading thought leaders in genetics and human
dysmorphology have been appointed to the steering committee of its Scientific Advisory
Board (SAB). These appointments further strengthen the SABs strategic role in assisting
FDNA on its mission to save lives and improve the quality of life of patients with rare or
difficult-to-diagnose genetic syndromes.

“Our SAB plays a pivotal role in shaping our vision and offering for next generation
computer-aided dysmorphology analysis. The addition of these leading experts to our
scientific advisory board further underscores our commitment to continue offering our
Facial Dysmorphology Novel Analysis (FDNA) technology free to the genetics expert
community.” said Dekel Gelbman, CEO of FDNA Inc. “With the support of our SAB and in line
with our community commitment, we are offering Face2Gene(TM), our free mobile search and
reference application, designed to accelerate and increase confidence in dysmorphology
evaluations”.

Leading Genetics Experts added to FDNA’s SAB:

Prof. Dian Donnai, CBE, FMedSci, FRCP
Prof. Donnai is Professor of Medical Genetics at the University of Manchester and Clinical
Head of Saint Mary’s Division/Consultant Manchester Centre for Genomic Medicine at Central
Manchester University Hospitals NHS Foundation Trust.

Prof. Arnold Munnich, MD, PhD
Prof. Munnich is Director of the Department of Genetics at Hospital Necker, University
Paris-Descartes. He is the Director of an INSERM Research Laboratory. Prof. Munnich is on
the editorial board of the Journal of Medical Genetics, European Journal of Human
Genetics, Human Genetics, Clinical Genetics and Human Molecular Genetics. He served as
advisor to the former President of the French Republic, Nicolas Sarkozy.

Prof. Jill Clayton-Smith, MD, MB ChB, MRCP, FRCP
Prof. Clayton-Smith is Consultant Clinical Geneticist at North Western Regional Genetic
Service, Honorary Professor in Medical Genetics and Clinical Lead for Research at Saint
Mary’s Division/Consultant Manchester Centre for Genomic Medicine at Central Manchester
University Hospitals NHS Foundation Trust. Prof. Clayton-Smith

Dr. Sofia Douzgou, MD
Dr. Douzgou is a consultant at the Manchester Centre for Genomic Medicine at Central
Manchester University Hospitals NHS Foundation Trust. She is co-organizer of the
International Manchester Dysmorphology Course and Conference and has assisted the
Orphanet.

“It is a pleasure for me, as the chairman of FDNA’s scientific advisory board, to
welcome these distinguished European genetics experts as members of the steering
committee.” said Dr. Michael R. Hayden, CM, OBC, FRSC, Chairman of FDNA’s Scientific
Advisory Board & Steering Committee. “I look forward to working with the new members in
advising FDNA’s management in providing new and valuable tools for the new era of clinical
dysmorphology.”

About FDNA
FDNA’s mission is to save lives and improve the quality of life of patients with rare or
difficult-to-diagnose genetic syndromes. FDNA(R) has developed the proprietary Facial
Dysmorphology Novel Analysis technology. This cutting-edge technology facilitates
comprehensive analyses of dysmorphic features and recognizable patterns of human
malformations from facial photos. Using advanced learning algorithms, the technology
improves over time, referencing comprehensive phenotype databases in real-time.

Using the power of cloud-computing and a HIPAA compliant community platform, FDNA
brings this innovation to mobile devices. FDNA’s solutions aid and empower in accelerating
and increasing confidence in the research and investigation of genetic syndromes while
leveraging the ever-increasing amounts of data in human genetics and dysmorphology.

Face2Gene is a search and reference tool provided for informational purposes and not
intended to replace clinician’s judgment or experience, nor should it be used to diagnose
or treat medical conditions.

        Contact:
        FDNA Inc.
        Yaron Front, V.P. Marketing
        Tel: +1-347-305-0085
        yaron.front@fdna.com

http://www.fdna.com

SOURCE FDNA Inc.


Source: PR Newswire



comments powered by Disqus